A low-cost, off-patent drug stops postpartum hemorrhage. Thousands of women's lives can be saved by making it available to traditional midwives through local businesses in developing countries.
What is the issue, problem, or challenge?
Each year, over twice as many women die in childbirth as people who died in the 2004 tsunami. 99% of these deaths are in developing countries and hemorrhage is the most common cause worldwide. Bleeding can be controlled in a clinic but we have shown that traditional midwives can use inexpensive misoprostol tablets to save lives in a woman’s home: where most births take place and most maternal deaths occur in the developing world--well beyond reach of hospitals and government health services.
How will this project solve this problem?
In 2004, we co-sponsored a successful policy meeting with the Kenyan government, at their request. Now we are preparing to work with manufacturers and to help with the regulatory process to make misoprostol available to save women’s lived.
Potential Long Term Impact
The project is uniquely scalable. Kenya been unable to lower maternal death to meet the U.N.'s 2015 goal of 75% reduction. With this drug, traditional midwives get their first effective technology and see the first major reduction in mortality.
Total Funding Received to Date: $576
This project is now in implementation and no longer available for funding. Received funds will be used to accomplish concrete objectives as indicated in the project's "Activities" section. Updates will be posted under the "Project Report" tab as they become available.
Donors' contributions and pledges to this project totaled $576 . The original project funding goal was $15,000.